NASDAQ · IFRX
InflaRx N.V.
$1.72-$0.02 (-0.87%)
InflaRx N.V.’s quoted price sits in the lower half of its reported 52-week range, 41.86% below the high.
Loading market information…
NASDAQ · CRDL · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Cardiol Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Cardiol Therapeutics Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.06. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cardiol Therapeutics Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Mar 31, 2025 |
| -$0.07+12.5% vs estimate |
| $0.00 |
| Q3 2024 | Nov 14, 2024 | -$0.13-30.0% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.72-$0.02 (-0.87%)
InflaRx N.V.’s quoted price sits in the lower half of its reported 52-week range, 41.86% below the high.
$23.50$0.00 (0.0%)
Assertio Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$1.14$0.00 (0.0%)
Vivani Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.67% below the high.
$1.12$0.00 (0.0%)
Microbot Medical Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.84% below the high.
$0.74-$0.04 (-5.23%)
Hyperfine, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.67% below the high.
$0.84-$0.01 (-1.17%)
Connect Biopharma Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 78.13% below the high.
$4.12-$0.35 (-7.83%)
InterCure Ltd.’s quoted price sits in the lower half of its reported 52-week range, 45.43% below the high.
$2.13+$0.12 (+5.97%)
Kalaris Therapeutics Inc’s quoted price sits in the lower half of its reported 52-week range, 82.07% below the high.
